Simplifying Complexity
Biomarker Discovery & Custom Assay Development for Origin-Specific Liquid Biopsies™ and Biomanufacturing
Adeptrix is a technology company that specializes in multiomic and multiparametric immunoassays for biofluids
Learn moreAbout us
We are a bioanalytical company in Beverly MA. Our proprietary high molecular resolution immunoassay technologies (BAMS™ and exoBAMS™) are designed for rapid “molecular fingerprinting” of populations of biological particles (exosomes, other extracellular vesicles (EVs), microbes, human cells) and other complex biological targets.
Vision
- A human body consists of trillions of cells, which form hundreds of distinct cell populations
- Cell populations continuously secrete tiny particles (known as extracellular vesicles or EVs) into blood and other biofluids. Contents of EVs reflect the health status of their parental cells
- By measuring EVs produced by specific cell populations “remote diagnostics” of multiple tissues and organs via a simple blood test becomes possible
Technology
- BAMS™ is an advanced immunoassay platform for analyzing complex bioanalytical targets that require data-rich, multiparametric readouts.
- exoBAMS™ is designed specifically for analyzing exosomes and other types of extracellular vesicles (EVs) .
- BAMS™ and exoBAMS™ are protected by US Patents 12,467,930, 12,019,070, 11,913,964, 11,639,938, 11,391,729, 11,131,674, 10,451,631, 10,101,336 and 9,618,520.
- Other US and international patents pending.
Sensitive
Reliably measures rare (below 0.1% abundance) analytical targets: can find a “needle in a haystack”. In liquid biopsies able to isolate plasma biomarkers released by a specific tissue, organ or a group of cells
Multiparametric
Can detect and quantify 100’s of distinct analyte signals in a label-free format
Reproducible
Below 10% CV, achieved via antibody-based target recognition and assay miniaturization
Fast
Data acquisition times of less than 1 second, ideal for high-throughput operations
Multiomic
Metabolomic, lipidomic, proteomic, glycomic* (under development)
AI/ML-ready
1,000’s of generated high-content datasets provide an extensive supply of biomarker candidates, which can be rapidly identified and validated using existing AI-driven software solutions
exoBAMS™ Technology Implementation Pipeline
Oncology
lung, colon, prostate, liver, breast, pancreas
Autoimmune Diseases
Inflammatory bowel disease, multiple sclerosis, lupus, rheumatoid arthritis
Neurodegenerative Diseases
Alzheimer’s Disease, Parkinson’s Disease
Metabolic diseases
Obesity, diabetes
And much more...
Industries Served
Disease Biology
- Creating unique molecular fingerprints for disease diagnosis, prognosis, staging and drug response
- Bridging the gap between solid and liquid biopsies by developing origin-specific liquid biopsies™
Synthetic Biology
- High-content, high-throughput monitoring of cell cultures, bioreactors and organ-on-a-chip systems
- Seamless assay transition from cell cultures to animal models and human studies
Case Studies
- Case Studies 1-4
- Case Studies 5-6 (coming soon)
What are extracellular vesicles (EVs) and extracellular particles (EPs)?
Cells release a spectrum of extracellular entities that ferry proteins, nucleic acids and other biomolecules between cells.
Representative membraneous EVs include exosomes (30-150 nm), microvesicles (100-1,000 nm) and larger particles that can reach micrometer size.
Representative non-vesicular particles include exomeres (~35 nm) and supermeres (15-25 nm). They lack a limiting membrane yet carry distinct protein and nucleic acid cargo.
Partner with us on Custom Pilot Projects
We are currently opening a select number of slots for custom analytical assay pilot projects. By partnering with us, your team gains access to dedicated development resources to build, optimize, and validate an exoBAMS™ assay tailored specifically to your unique R&D goals.
Whether you are looking to profile specific exosome surface markers or streamline your bioanalytical workflows, we can build the exact tool you need to accelerate your pipeline.